{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 120 of 128', 'on financial interests during the course of the clinical trial and for 1 year after completion of', 'the clinical trial, or for a longer period of time if required by local legislation.', 'Appendix 3H: Trial and site closure', 'Premature termination of trial or trial site', 'LEO, the investigator, the IRB/IECs or competent authorities may decide to stop the clinical', 'trial, part of the trial or a trial site at any time, but agreement on procedures to be followed', 'must be obtained.', 'If a clinical trial is suspended or prematurely terminated, the investigator must inform the', 'subjects promptly and ensure appropriate therapy and follow-up. As specified by applicable', 'regulatory requirements, the investigator or LEO must promptly inform IRB/IECs and', 'provide a detailed written explanation. Relevant competent authorities must be informed.', 'The trial must be terminated if the perception of the benefit/risk ratio (judged from clinical', 'signs and symptoms, (S)AEs and/or remarkable safety laboratory changes) becomes', 'unfavourable for the continuation of the trial.', 'Reasons for the early closure of a trial site by LEO or investigator may include but are not', 'limited to:', 'Failure of the investigator to comply with the protocol, the requirements of the', 'IRB/IEC or local health authorities, LEO procedures, or GCP guidelines.', 'Inadequate recruitment of subjects by the investigator.', 'Completion of trial', 'Investigators will be informed when subject recruitment is to cease. Screening activities will', 'be stopped at a trial site when the total requested number of subjects for the clinical trial or', \"participating country has been obtained, irrespective of the specific site's planned inclusion\", 'number.', 'Trial sites will be closed upon trial completion. LEO will undertake arrangements for the', 'collection and disposal of any unused trial material that the investigator is not required to', 'keep in his/her files. A trial site is considered closed when all required documents and trial', 'supplies have been collected and a trial site closure visit has been performed.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 121 of 128', 'When the randomisation code has been broken, the investigators will receive information', 'about the treatment allocation for the subjects randomised at their respective sites and will be', \"asked to record this in the subject's medical record.\", 'Appendix 3I: Responsibilities', 'The signatory investigator is responsible for the approval of the clinical trial protocol and', 'the CTR on behalf of all clinical trial investigators and as agreed to in a Signatory Investigator', 'Agreement.', 'The national coordinating investigators are responsible for national issues relating to the', 'clinical trial as agreed to in a National Coordinating Investigator Agreement.', 'Each participating investigator is responsible for all aspects of the clinical trial conduct at', 'his/her trial site as agreed to in a Clinical Trial Agreement.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 122 of 128', 'Appendix 4: Short version of eligibility criteria', 'This appendix provides a short form (maximum 200 characters) of each of the eligibility', 'criteria to be used when data are submitted to regulatory authorities in CDISC format.', 'Inclusion criteria', 'No.', '1', 'Signed and dated informed consent has been obtained prior to any protocol-related procedures.', '2', 'Age 18 years or above.', '3', 'Diagnosis of chronic hand eczema defined as hand eczema, which has persisted for more than', '3 months or returned twice or more within the last 12 months.', '4', 'Disease severity graded as mild to severe according to IGA (i.e., an IGA score of 2 or more).', '5', 'Recent history (within 1 year before the screening visit) of inadequate response to topical', 'corticosteroid treatment or topical corticosteroid treatment being medically inadvisable.', '6', 'Diagnostic patch testing performed within 3 years prior to the screening visit.', '7', 'A woman of childbearing potential must use a highly effective form of birth control throughout the', 'trial and at least for 2 weeks after last application of IMP.', 'Exclusion criteria', 'No.', '1', 'Concurrent skin diseases on the hands, e.g. tinea manuum.', '2', 'Active atopic dermatitis in regions other than the hands or psoriasis requiring medical treatment.', '3', 'Clinically significant infection (e.g., impetiginised hand eczema) on the hands.', '4', 'Systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, or', 'corticosteroids within 4 weeks prior to baseline.', '5', 'Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4 weeks prior to', 'baseline.', '6', 'Receipt of live attenuated vaccines 4 weeks prior to baseline.', '7', 'Cutaneously applied treatment with immunomodulators (e.g., PDE-4 inhibitors, pimecrolimus,', 'tacrolimus) or topical corticosteroids on the hands within 2 weeks prior to baseline.', '8', 'Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 2 weeks prior to', 'baseline.', '9', 'Change in systemic antihistamine therapy within 2 weeks prior to baseline i.e., subjects must not', 'start antihistamine treatment or change the current dosage regime within 2 weeks prior to baseline.', '10', \"Other cutaneously applied therapy on the hands (except for the use of subject's own emollients)\", 'within 1 week prior to baseline.', '11', 'Cutaneously applied treatments in regions other than the hands, which could interfere with clinical', 'trial evaluations or pose a safety concern within 1 week prior to baseline.', '12', 'Receipt of any marketed or investigational biologic agents within 6 months or 5 half-lives prior to', 'baseline or until cells counts returns to normal, whichever is longer.']\n\n###\n\n", "completion": "END"}